1. Clinical Effectiveness & High Cost Drugs
Introduction from Roelof Konterman
Vice-Chairman of the Executive Board & Head of Health, Achmea

2. Current Members
These are all the “active members” – there have been others attending, but only once and not recently…
Perhaps mention we are meeting in Stockholm 5th – 7th September and we could welcome a few new members. To contact Nicola Jedrej at iFHP. Good advertising. Mention Karolinska Institute if you think this is possibility to visit.

3. Background
Initially two separate Panels, which both first met in December 2015, as High Cost Drugs and New Medical Technologies
Now established as High Cost Drugs and Clinical Effectiveness, meeting at least once a year
You could mention here that there was consensus to combine both Panels, as many of the Panel members are involved in the procurement of both drugs and technologies and covered both areas in their roles.
Also perhaps mention that the name was amended from New Medical Technologies as the focus shifted from “New” to “Effectiveness” and was centred around the benefits and outcomes of all treatments whether they are new or existing

4. Current issues Topics discussed include, but are not limited to:
- Volume of treatments needed to improve patient outcomes
- How to grade and access the merit of new and existing technologies
- Establishing where there is benefit for knee arthroscopy
- Gaining a better understanding of when and how to obtain better value from robotic surgery (Da Vinci)
- Comparing outcomes between “at home” treatments vs traditional hospital settings
- The impact of political advocacy & communication relating to High Cost Drugs
- Reviewing the pipeline of High Cost Drugs entering the market
These are not all, but a good selection for people to get a flavour of the Panels discussions
I have made the “Horizon Scanning” pipeline the last point which will lead onto Lizzie Tuckey’s presentation and allow you to introduce her.
Lizzies full title is:
Dr Lizzie Tuckey
Director of Clinical Strategy
Bupa
The Horizon Scanning Project is the first time the iFHP has had a cross company piece of research. Five companies took part from the Panel, with IMS Quintiles Consultancy leading the research and delivering the findings.
Lizzie can take you through this now in greater detail.